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Abstract
Background: Ephrin receptor B2 (EPHB2) has recently been proposed as a novel tumor suppressor
gene in colorectal cancer (CRC). Inactivation of the gene has been shown to correlate with
progression of colorectal tumorigenesis, and somatic mutations have been reported in both
colorectal and prostate tumors.
Methods: Here we have analyzed the EPHB2 gene for germline alterations in 101 individuals either
with 1) CRC and a personal or family history of prostate cancer (PC), or 2) intestinal hyperplastic
polyposis (HPP), a condition associated with malignant degeneration such as serrated adenoma and
CRC.
Results: Four previously unknown missense alterations were observed, which may be associated
with the disease phenotype. Two of the changes, I361V and R568W, were identified in Finnish CRC
patients, but not in over 300 Finnish familial CRC or PC patients or more than 200 population-
matched healthy controls. The third change, D861N, was observed in a UK HPP patient, but not
in additional 40 UK HPP patients or in 200 UK healthy controls. The fourth change R80H, originally
identified in a Finnish CRC patient, was also found in 1/106 familial CRC patients and in 9/281
healthy controls and is likely to be a neutral polymorphism.
Conclusion: We detected novel germline EPHB2 alterations in patients with colorectal tumors.
The results suggest a limited role for these EPHB2 variants in colon tumor predisposition. Further
studies including functional analyses are needed to confirm this.
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Background
The Wnt signaling pathway plays a central role in the
development of colorectal cancer (CRC). In the majority
of cases the early events in tumorigenesis involve inactiva-
tion of the tumor suppressor gene APC and stabilization
of β-catenin [1,2]. The constitutive activity of β-catenin/T
cell factor-4 (Tcf-4) –complex leads to transcription of
growth promoting genes, which together with subsequent
inactivation of tumor suppressor genes drive the tumori-
genesis further and enable the formation of abnormal
growth patterns.
One of the direct transcriptional targets of β-catenin is
Ephrin receptor B2 (EPHB2), whose protein product medi-
ates the bi-directional migration and correct positioning
of the cells along the crypt axis in the intestinal epithelium
[3]. The gene is located in chromosomal region 1p36,
which is frequently altered in many types of cancer [4].
Recent findings have demonstrated that EPHB2 appears to
have a role in tumor progression, and acts as a tumor sup-
pressor gene in colorectal cancer. In the study by Batlle et
al. (2005) EPHB2 activity was observed to suppress CRC
progression as the disruption of EphB2 in Apcmin/+ mice
was shown to accelerate tumor formation and growth in
colon and rectum [5]. In addition, premalignant lesions
of the colon were shown to express high levels of EPHB2,
whereas the expression was reduced in more advanced
tumor stages [5]. Somatic mutations in EPHB2 have been
observed both in colorectal and prostate tumors, and an
EPHB2 germline mutation has been associated with an
increased prostate cancer (PC) risk [6-8]. Huusko et al.
(2004) identified a nonsense mutation Q723X in a PC
cell line, which led to the identification of other novel
missense (R199H, A297S, D679N, T909M), nonsense
(K1019X), frameshift and splice site mutations in prostate
tumors obtained from patients in USA and Switzerland
[7]. In a later study by Kittles et al. (2005) the nonsense
mutation K1019X was found to increase risk for PC over
two-fold in an African American hereditary PC sample set
[8]. In 2005, Alazzouzi et al. observed frequent frameshift
mutations on the A9 repeat of the EPHB2 gene in primary
colorectal tumors in patients of mostly Caucasian origin
(Finland, Germany, Spain and Japan) [6].
In our recent study we found decreased EPHB2  gene
expression and protein levels in tumors with serrated CRC
when compared to tumors from patients with conven-
tional CRC [9]. While no somatic EPHB2 mutations were
observed in the serrated CRC tumors, one patient was
found to harbor a germline EPHB2  alteration. This,
together with the growing evidence of the role of EPHB2
in CRC tumorigenesis, prompted us to further investigate
the role of EPHB2 in colorectal tumor predisposition. In
this study, we have analyzed the EPHB2 gene for germline
alterations in 101 patients with either 1) CRC and per-
sonal or family history of PC or 2) hyperplastic polyposis
(HPP), a condition believed to be associated with serrated
CRC [10].
Methods
Patient material
Altogether 101 normal tissue samples were collected from
medical institutions in Finland, UK and USA from
patients with 1) CRC and either personal or family history
of PC (n = 63, mean age of onset 69 years, range 30–85
years) or 2) hyperplastic polyposis (n = 38, mean age of
onset 46 years, range 16–69) (Table 1). The CRC patients
belong to a well characterized and previously described
population based series of 1042 Finnish CRC patients
[11,12]. Family history of PC was considered positive if
the patient had a first degree relative diagnosed with PC.
HPP was diagnosed if there were at least three but typi-
cally over 10 histopathologically verified hyperplastic pol-
yps. If less than five polyps were observed, at least two of
them had to be large (>1.0 cm). The UK patients had
between 10 to over 100 HPs, and the mean age of onset
was 43 years (range 16–79 years). Five patients had one or
more large HPs (range 1–3 cm), two had serrated adeno-
mas, one had mixed adenomatous/hyperplastic polyps,
three had adenomas and one had juvenile polyps. Family
history of polyps or cancer was detected in 10% of these
individuals, and 40% of these had developed CRC.
Patients from the US had in general over 30 HPs, the
Table 1: Selection criteria of the 101 patients screened for germline EPHB2 mutations.
Selection criteria Number of patients Country of origin
Patients with HPP* 38
HPP 12 USA
HPP 24 UK
HPP 2F I N
Patients with CRC* and personal or family history of PC* 63
CRC in the patient and PC in the family 52 FIN
CRC and PC in the same patient 11 FIN
*HPP = hyperplastic polyposis, CRC = colorectal cancer, PC = prostate cancer.BMC Cancer 2006, 6:145 http://www.biomedcentral.com/1471-2407/6/145
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mean age at HPP diagnosis was 51 years (range 19-68
years), and all but one had been diagnosed with serrated
adenomas. In two cases there was history of HPP in the
family. The two Finnish HPP patients were diagnosed
with multiple hyperplastic polyps and serrated adenomas
at 44 and 41 years of age.
The frequencies of the observed EPHB2 variants were fur-
ther analyzed in either Finnish familial prostate (n = 164,
mean age of onset 63 years, range 40–86 years) and color-
ectal (n = 159, mean age of onset 65 years, range 27–90
years) cancer patients, or in additional UK HPP patients
(n = 40, mean age of onset 54 years, range 23– 74), respec-
tively. The Finnish CRC patients belong to the aforemen-
tioned population based series of CRC patients [11,12].
The familial PC cohort has also been previously well char-
acterized and described [13,14]. In addition, 282 samples
from anonymous Finnish blood donors and 200 healthy
UK individuals served as population-matched controls,
respectively.
Patient information and samples were collected after
obtaining informed consent. The study was approved by
the ethics review committee of the Hospital District of
Helsinki and Uusimaa (Dnr. 133/E8/03).
Mutation analysis
Mutation screening of the EPHB2  gene [GenBank:
AF025304] in the 101 normal tissue samples was per-
formed by direct sequencing (ABI PRISM 3100 Genetic
Analyzer, Applied Biosystems, Foster City, CA). All coding
exons with at least 70 nucleotides intronic sequence at the
exon-intron boundaries, except exon 1, were sequenced.
Primer sequences and PCR conditions are available upon
request. Loss of heterozygosity (LOH) was analyzed by
comparing sequences from the normal and the corre-
sponding tumor DNA at the site of a variant. Frequencies
of the observed alterations in familial CRC, PC and HPP
patient samples, as well as in healthy population-matched
controls, were determined by either direct sequencing or
DHPLC (variant R568W). The DHPLC analysis was per-
formed using the Agilent 1100 Services DHPLC Instru-
mentation (Agilent, Palo Alto, CA) with HPLC Column
50 × 3.0 mm × ¼" Helix DNA (Varian, Palo Alto, CA),
Helix BufferPak DNA Analysis buffers "A" and "B" (Var-
ian), and the following parameters: T = 64°C, flow 0.4 ml/
min, gradient 3 min 58–66% B-buffer.
Results
Altogether four heterozygous germline missense changes,
all previously unreported, were observed in the initial
EPHB2 mutation screening of 101 samples (Table 2). An
I361V (1081A>G) alteration in exon 5 was detected in a
Finnish patient diagnosed with a microsatellite stable
(MSS) rectal cancer at the age of 75 years and PC at the age
of 73 years. The variant was not present in 164 familial PC
patients, in 139 of 159 familial CRC patients (data from
87% of cases) or in 239 of 282 healthy population-
matched controls (data from 85% of cases). The corre-
sponding tumor tissue displayed loss of the wild type
allele. This residue resides in the fibronectin type III
domain, which is in the extracellular part of the protein
and participates in cell-surface binding. Another missense
change, R568W (1702C>T) in exon 9, was detected in a
Finnish patient diagnosed with a MSS colon cancer at the
age of 69 years. The patient's father, whose carrier status is
unknown, had been diagnosed with PC at the age of 82
years. The variant was not observed in 164 familial PC
patients, in 145 familial CRC patients (data from 91% of
cases), or in 279 healthy Finnish controls. No loss of the
wild type allele was observed in the colon tumor tissue.
The residue is located in a juxtamembrane segment before
a kinase domain in the intracellular part of the protein.
The third missense alteration, D861N (2581G>A) in exon
Table 2: Observed EPHB2 germline variations in colorectal cancer and hyperplastic polyposis patients.
Patient Exon nt change aa change Index patient 
(diagnosis, age at 
diagnosis, nationality)
Family history of 
cancer
LOH Frequency in
familial PC* familial CRC* healthy controls
C713 3 239G>A R80H CRC, 73 years, FIN brother, PC, 60 
years father, GC*, 
57 years
no - 1/106 9/281
C112 5 1081A>G I361V CRC, 75 years and PC, 
73 years, FIN
- yes 0/164 0/139 0/239
C809 9 1702C>T R568W serrated CRC, 69 years, 
FIN
father, PC, 82 years no 0/164 0/145 0/279
PAP211 14 2581G>A D861N HPP*, 58 years, UK mother, CRC, 36 
years
- - 0/40† 0/200
* CRC colorectal cancer; HPP hyperplastic polyposis; PC prostate cancer; GC gastric cancer.
† frequency in additionally screened 40 UK HPP patientsBMC Cancer 2006, 6:145 http://www.biomedcentral.com/1471-2407/6/145
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14, was detected in a UK patient diagnosed with HPP at
the age of 58 years. A review of her clinico-pathologic his-
tory revealed that, to date, she has had serrated adenomas
and over 100 pancolonically distributed sessile HPs. The
patient's mother, from whom no sample was available,
had died of CRC at the age of 36 years. The variant was not
observed in the additional 40 HPP patients or in 200
healthy UK controls. Due to the unavailability of tumor
tissue DNA, LOH could not be determined. The variant is
located in the intracellular protein kinase domain of
EPHB2. The fourth change, R80H (239G>A) in exon 3,
was initially observed in a Finnish patient whose MSS
colon cancer was diagnosed at the age of 73 years. The
patient's brother had been diagnosed with PC at the age of
60 years, and her father had died of gastric cancer at the
age of 57 years. The variant was also found in 1/106
(0.9%) familial CRC patients and in 9/281 (3.2%)
healthy population-matched controls. No loss of the wild
type allele was observed in the tumor tissue. The variant is
situated in the N-terminal ligand-binding domain at the
extracellular part of the protein.
Discussion
Ephrin receptors constitute a large family of receptor pro-
tein tyrosine kinases that together with ephrins, their
membrane-bound receptor-like ligands, participate in
developmental processes requiring organized patterning
and movement of cells, such as axonal guidance, signal
transduction, cell morphogenesis and angiogenesis
[15,16]. These proteins are widely expressed in adult tis-
sues with organ specific patterns [17]. In the intestine the
most prominent ephrin receptor is EPHB2 [17]. Recently,
the loss of EPHB2 expression has been associated with
colorectal carcinogenesis. The reduction of the EPHB2 lev-
els has been found to correlate with the degree of malig-
nancy, as a significant decrease in number of EPHB2
positive cells and in staining intensity has been observed
at the adenoma-carcinoma transition [5,18,19]. In our
recent study, we found even more profound reduction in
EPHB2 levels in colorectal tumors with serrated histology
when compared to conventional CRC [9]. The link
between reduced EPHB2 expression and poor survival has
also been demonstrated [19]. In mouse studies, reduced
Ephb2 activity has been shown to accelerate tumorigene-
sis in the colon and rectum, and to result in the formation
of aggressive adenocarcinomas in ApcMin/+ mice [3]. Based
on the growing evidence of the role of EPHB2 in CRC, we
hypothesized that EPHB2 germline alterations may pre-
dispose to colorectal tumors.
We found a total of four previously unknown EPHB2
germline alterations, of which three may associate with
the disease phenotype. The corresponding tumor DNA
was available from two variant carriers, and one of the
tumors displayed loss of the wild type allele. All three
alterations are located in amino acids showing conserva-
tion across species from mouse, rat, chicken and cow
down to fish, and were not observed in more than 200
healthy population-matched controls. However, the pos-
sibility that some or all of these variants are rare polymor-
phisms cannot be excluded, and further studies are
needed to elucidate their functional significance.
In Finland, occurrence of recurrent founder mutations in
several cancer susceptibility genes has been successfully
utilized to evaluate the impact of these gene defects in
extensive sets of patients and families [11,12,20]. There-
fore, to further analyze the importance of the EPHB2 var-
iants observed in the Finnish patients (I361V and
R568W), their frequencies were analyzed among more
than 300 Finnish familial CRC and PC patients. No addi-
tional carriers were observed. This suggests that the contri-
bution of these rare germline alterations to familial CRC
and PC burden in Finland is limited. The UK variant
D861N was not observed in additional 40 HPP patients or
in 200 healthy UK controls, suggesting as well a possible
role for the variant in colorectal tumor susceptibility.
Overall, germline variants that may be associated with the
disease phenotype were seen in 3/101 (3.0%) of patients
analyzed for the EPHB2 gene. Our data are compatible
with the results by Oba et al. (2001), who found no
EPHB2 germline mutations among 50 CRC patients [21].
Therefore, although some possibly disease associated
germline EPHB2 variants do exist and may play a role in
colorectal tumor predisposition, the observed EPHB2
inactivation in CRCs is largely due to other mechanisms,
such as promoter hypermethylation that has frequently
been observed in both MSI and MSS tumors, LOH, and
somatic mutations in a coding region repeat sequence in
MSI colorectal tumors [6,18].
While EPHB2 is the prominent ephrin receptor in the
intestine [17], also other members of the protein family
may have a role in colorectal tumorigenesis. For example,
a dramatic 94-fold decrease in EPHA6 expression has
been observed in colorectal tumors when compared to
normal tissue, and EPHA8 expression has been detected
only in colon tumor but not in corresponding normal tis-
sue [17]. Furthermore, a pattern of inactivation similar to
EPHB2 has been observed for EPHB4 and EPHB3 in color-
ectal tumors and/or cell lines, respectively [5]. Also
somatic mutations in the kinase domain of EPHA3 have
been identified in colorectal tumors [22]. Further studies
are needed to more thoroughly elucidate the possible role
of this large protein family in CRC tumorigenesis.
Conclusion
We report here the first EPHB2 germline alterations in
patients with colorectal tumors. However, the rarity ofBMC Cancer 2006, 6:145 http://www.biomedcentral.com/1471-2407/6/145
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such alterations in this and in a previous study [21],
together with the sequential loss of EPHB2 expression
during colorectal carcinogenesis, suggests a limited role
for EPHB2 in CRC predisposition and speaks for the more
pronounced role for EPHB2 in tumor progression than in
tumor initiation. Notwithstanding, germline EPHB2 vari-
ants do exist and may be associated with colon tumor pre-
disposition, but further studies including functional
analyses are needed to confirm this.
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